Head-to-head evidence
Ametinib vs H002
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Ametinib
Developed by Hansoh Pharmaceutical Group and partners
NCT05754736 · Phase 2 · status unknown
This is a single-arm, open-label study with no comparator group, so there is no way to know whether the combination performs better than existing treatments. Results on tumor response and progression-free survival have not yet been posted.
H002
Developed by RedCloud Bio
NCT05519293 · Phase 1/2 · status unknown
A non-randomized, open-label, sequential-cohort phase 1/2 study of H002 with an estimated 76 participants and no results posted to the registry. With no comparator arm and no posted results, this is weak evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ametinib's landscape · H002's landscape